Palliative Care in Hemolytic Disease: A Clinically Oriented Review

 Palliative Care in Hemolytic Disease: A Clinically Oriented Review

Author: Dr. Shekhar and team Doctor's forum for all 🏥 

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation.

Abstract

Hemolytic disease encompasses a wide spectrum of inherited and acquired disorders characterized by premature destruction of red blood cells. Common examples include sickle cell disease, thalassaemia, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, autoimmune haemolytic anaemia, and severe haemolytic disease of the fetus and newborn. Although disease-modifying therapies—such as transfusion, iron chelation, immunomodulation, and intrauterine transfusion—have improved survival, many patients still experience significant pain, fatigue, organ dysfunction, psychological distress, and reduced life expectancy. Palliative care is therefore an essential, concurrent layer of support rather than an end-of-life-only intervention. This article reviews the principles, symptom management, paediatric and perinatal considerations, advance care planning, and end-of-life care relevant to haemolytic disease.

1. Introduction

Palliative care is defined by the World Health Organization as an approach that improves the quality of life of patients and their families facing problems associated with life-threatening illness, through prevention and relief of suffering by early identification, impeccable assessment, and treatment of pain and other physical, psychosocial, and spiritual problems [1].

In haemolytic disease, red cell destruction leads to anaemia, jaundice, reticulocytosis, splenomegaly, and a range of downstream complications, including pigment gallstones, pulmonary hypertension, iron overload, stroke, and chronic pain. Patients with severe sickle cell disease, transfusion-dependent thalassaemia, refractory autoimmune haemolytic anaemia, and severe haemolytic disease of the newborn often have complex palliative needs that begin long before the terminal phase.

Modern palliative care should be integrated early and provided alongside disease-directed therapy. This is particularly relevant in haematological disorders, where the illness trajectory may be prolonged and punctuated by acute complications, but progressive organ damage eventually limits life expectancy [2,3].

2. Disease Spectrum and Palliative Triggers

2.1 Conditions Covered

· Inherited haemolytic anaemias: sickle cell disease, thalassaemia major/intermedia, hereditary spherocytosis, G6PD deficiency, pyruvate kinase deficiency.

· Acquired haemolytic anaemias: autoimmune haemolytic anaemia, alloimmune haemolytic disease of the newborn, microangiopathic haemolytic anaemia, drug-induced haemolysis.

· Severe haemolytic disease of the fetus/newborn (HDFN): caused by maternal red cell alloimmunization, leading to fetal anaemia, hydrops fetalis, and neonatal jaundice.

2.2 Palliative Care Triggers

Palliative care referral should be considered when a patient has:

· Recurrent severe vaso-occlusive pain episodes or chronic pain requiring opioid therapy.

· Transfusion dependence with poor venous access or recurrent transfusion reactions.

· End-organ damage such as pulmonary hypertension, renal failure, heart failure, or stroke.

· Progressive functional decline or poor performance status.

· Recurrent severe infections or sepsis.

· Severe HDFN with poor fetal/neonatal prognosis.

· Patient or family request for support with symptom burden, goals of care, or advance care planning.

· Limited life expectancy or eligibility for hospice.

Early involvement of palliative care in sickle cell disease and thalassaemia can improve symptom control, support families, and clarify treatment goals without reducing access to curative therapies [2,3].

3. General Principles of Palliative Care in Haemolytic Disease

1. Concurrent care: Palliative care should be provided alongside disease-modifying treatments, including transfusions, chelation, hydroxyurea, and transplantation where appropriate.

2. Interdisciplinary team: Haematologist, palliative care physician, pain specialist, nurse, social worker, psychologist, physiotherapist, and chaplain.

3. Holistic assessment: Regular assessment of physical symptoms, psychological distress, social needs, spiritual concerns, and caregiver burden.

4. Communication: Shared decision-making, honest prognostic discussions, and documentation of preferences.

5. Symptom-driven approach: Management should focus on the patient’s reported symptoms and quality of life, not only laboratory parameters.

4. Symptom Assessment and Management

4.1 Anaemia, Fatigue, and Transfusion Support

Chronic haemolysis causes anaemia, which contributes to fatigue, dyspnoea, reduced exercise tolerance, and poor quality of life.

Management:

· Transfusion: In the palliative setting, red cell transfusion can be used to relieve symptomatic anaemia, dyspnoea, and fatigue. Transfusion thresholds should be guided by symptoms rather than a fixed haemoglobin level. In sickle cell disease, phenotype-matched red cells are recommended to reduce alloimmunization [4].

· Fatigue management: Address reversible causes such as iron deficiency, folate deficiency, hypothyroidism, depression, and sleep disturbance. Energy conservation, physiotherapy, and psychological support are helpful.

· Dyspnoea: If due to anaemia, transfusion may improve symptoms. If dyspnoea persists despite transfusion, treatable causes such as heart failure, pulmonary hypertension, or infection should be sought. Opioids remain first-line pharmacological therapy for refractory dyspnoea in advanced disease [5].

· Iron chelation: In transfusion-dependent patients, iron overload is a major cause of cardiac, hepatic, and endocrine morbidity. In advanced or terminal disease, the burden of chelation may outweigh benefit; stopping chelation after careful discussion can improve quality of life [6].

4.2 Pain

Pain is one of the most common and distressing symptoms in haemolytic disease, especially in sickle cell disease. It may be acute vaso-occlusive pain, chronic bone pain, neuropathic pain, or pain from leg ulcers, splenic infarction, or gallstones.

Acute severe pain (e.g., sickle cell vaso-occlusive crisis):

· Rapid assessment and initiation of analgesia within 30 minutes of presentation is recommended [3].

· Parenteral opioids are the mainstay; patient-controlled analgesia may be appropriate in hospital.

· Reassess pain frequently and titrate opioids to effect, monitoring for sedation and respiratory depression.

· Non-opioid adjuvants such as paracetamol, NSAIDs (if no contraindication), and ketamine for refractory pain may be considered [7].

Chronic pain:

· Use a multimodal approach: long-acting opioids, non-opioid analgesics, and adjuvant drugs such as gabapentin, pregabalin, amitriptyline, or duloxetine for neuropathic pain.

· Non-pharmacological strategies include cognitive behavioural therapy, heat, massage, TENS, and physiotherapy.

· Pain management should be individualised, with attention to opioid side effects, tolerance, and risk of misuse.

End-of-life pain:

· Continuous subcutaneous infusion of morphine or diamorphine is commonly used in the dying phase.

· Midazolam may be added for terminal agitation or anxiety.

· Doses must be titrated against response; there is no fixed maximum dose for opioid therapy in palliative care [8].

4.3 Dyspnoea

Dyspnoea in haemolytic disease may result from severe anaemia, pulmonary hypertension, heart failure, acute chest syndrome, or end-stage lung disease.

Management:

· Treat reversible causes: transfusion for symptomatic anaemia, diuretics for heart failure, antibiotics for infection, oxygen if hypoxaemic.

· Non-pharmacological measures: a fan, open window, relaxation techniques, and positioning.

· Pharmacological therapy: low-dose oral or subcutaneous morphine is effective for refractory dyspnoea in advanced illness [5].

· Benzodiazepines may be used for associated anxiety, but are not first-line for dyspnoea alone.

4.4 Jaundice and Pruritus

Haemolysis causes unconjugated hyperbilirubinaemia and jaundice. Although unconjugated hyperbilirubin itself does not usually cause pruritus, chronic haemolysis can lead to pigment gallstones, biliary obstruction, or cholestasis, which may cause severe itching.

Management of pruritus:

· General measures: emollients, cool environment, avoidance of dry skin.

· Antihistamines may provide limited benefit but can help with sedation.

· Cholestyramine may be used if biliary obstruction is present.

· Rifampicin, naltrexone, or sertraline can be considered for refractory cholestatic pruritus [9].

· In terminal care, sedation may be needed if pruritus is severe and distressing.

4.5 Splenomegaly and Abdominal Symptoms

Splenomegaly is common in chronic haemolytic anaemias and may cause early satiety, abdominal discomfort, cytopenias, and splenic sequestration crises.

Acute splenic sequestration:

· More common in sickle cell disease, especially in children.

· Presents with rapid splenic enlargement, severe anaemia, hypovolaemic shock, and abdominal pain.

· It is a medical emergency; initial management includes fluid resuscitation and blood transfusion.

· In the palliative setting, recurrent sequestration may be managed conservatively if the patient is not a candidate for splenectomy.

Chronic splenomegaly:

· Pain management with simple analgesics and opioids as needed.

· Splenectomy may be curative or disease-modifying in hereditary spherocytosis, but in advanced or high-risk patients the surgical risk may outweigh benefit.

· Palliative radiation to the spleen is occasionally used in haematological malignancies but has limited evidence in benign haemolytic disease [6].

4.6 Iron Overload and Organ Dysfunction

Transfusion-dependent patients with thalassaemia major, sickle cell disease, or other chronic anaemias are at risk of iron overload, leading to:

· Cardiac: heart failure, arrhythmias.

· Hepatic: cirrhosis, liver failure.

· Endocrine: diabetes mellitus, hypogonadism, hypothyroidism.

Palliative management:

· Manage heart failure with diuretics, ACE inhibitors/beta-blockers if tolerated, and oxygen.

· Treat diabetes and endocrine deficiencies symptomatically.

· Review the indication for iron chelation in advanced disease. Discontinuing chelation may reduce treatment burden and improve comfort in the terminal phase [6].

· Pulmonary hypertension is a serious complication in sickle cell disease and thalassaemia, associated with high mortality. In the palliative context, management focuses on symptom relief: oxygen for hypoxaemia, diuretics for right heart failure, opioids for dyspnoea, and careful fluid balance [10].

4.7 Leg Ulcers and Wound Care

Leg ulcers are common in sickle cell disease and cause chronic pain, infection, odour, and impaired mobility.

Management:

· Gentle wound cleansing and debridement.

· Compression bandaging only if arterial disease has been excluded by ankle-brachial index.

· Control infection with appropriate antibiotics.

· Odour management with metronidazole gel or charcoal dressings.

· Analgesia for dressing changes and background pain [11].

· In advanced disease, the goal may shift to comfort and odour control rather than complete healing.

4.8 Priapism

Recurrent or prolonged priapism occurs in sickle cell disease and can cause severe pain and long-term erectile dysfunction.

Management:

· Acute priapism lasting more than 4 hours is a urological emergency requiring aspiration and irrigation with or without alpha-adrenergic agents.

· Recurrent stuttering priapism may be managed with hormonal therapy, alpha-agonists, or counselling.

· In the palliative setting, the focus should be on pain relief, psychological support, and urological referral when appropriate.

4.9 Psychosocial and Spiritual Distress

Chronic haemolytic disease is associated with anxiety, depression, social isolation, stigma, and financial strain. Patients may struggle with body image changes (jaundice, short stature, leg ulcers), frequent hospitalisations, and uncertainty about the future.

Management:

· Routine screening for depression and anxiety.

· Psychological therapies, including cognitive behavioural therapy and counselling.

· Pharmacological treatment with SSRIs or other antidepressants when indicated.

· Spiritual care, including chaplaincy, meaning-making, legacy work, and cultural rituals.

· Support for family caregivers, including respite care and bereavement support.

5. Perinatal and Paediatric Palliative Care in Haemolytic Disease

5.1 Severe Haemolytic Disease of the Fetus/Newborn

Severe HDFN can lead to fetal anaemia, hydrops fetalis, and neonatal jaundice. Intrauterine transfusion has dramatically improved survival, but some cases remain life-limiting, especially when there is severe early hydrops, fetal brain injury, or parental refusal of invasive interventions [12].

Perinatal palliative care should be offered when:

· There is severe fetal anaemia/hydrops with poor prognosis.

· Intrauterine transfusion is not feasible or has failed.

· There is severe associated congenital anomaly or brain injury.

· Parents choose comfort-focused care after counselling.

Key elements of perinatal palliative care:

· Multidisciplinary counselling involving obstetrics, neonatology, haematology, and palliative care.

· Birth planning: location, mode of delivery, resuscitation preferences, presence of family.

· Memory-making: photographs, handprints, baptism/blessings according to family wishes.

· Bereavement support before and after death [13].

5.2 Neonatal Palliative Care

If the newborn has severe HDFN with multi-organ failure or is not responding to therapy, neonatal palliative care focuses on:

· Pain management using sucrose, paracetamol, and opioids as needed.

· Management of respiratory distress with oxygen and opioids.

· Skin care and temperature regulation.

· Support for parental bonding and family time.

· Withdrawal of intensive care if agreed, with attention to comfort medications such as morphine and midazolam.

5.3 Paediatric Sickle Cell Disease and Thalassaemia

Children with severe sickle cell disease may experience frequent pain crises, acute chest syndrome, stroke, and cognitive impairment. Paediatric palliative care can be introduced at diagnosis for high-risk patients and is not limited to end of life. It provides symptom management, school support, psychological care, and family support.

6. Advance Care Planning and End-of-Life Care

6.1 Advance Care Planning

Advance care planning should begin early in the course of life-limiting haemolytic disease, ideally when the patient is stable. It includes:

· Discussion of goals of care and values.

· Documentation of preferences for cardiopulmonary resuscitation, mechanical ventilation, and intensive care.

· Preferences for transfusion in the terminal phase.

· Preferred place of care and death.

· Appointment of a healthcare proxy or lasting power of attorney.

In sickle cell disease, patients may have strong views about pain management and hospital admissions; these should be documented and respected [3].

6.2 Recognising the Terminal Phase

Features suggesting that a patient with haemolytic disease is entering the terminal phase include:

· Progressive decline in performance status.

· Repeated hospital admissions despite optimal therapy.

· Refractory anaemia with poor response to transfusion.

· Worsening organ failure (cardiac, hepatic, renal, pulmonary).

· Recurrent severe infections or sepsis.

· Patient expresses wish for comfort-focused care.

6.3 Symptom Control in the Last Days of Life

Common symptoms in the dying phase include pain, dyspnoea, terminal agitation, respiratory secretions, nausea, and vomiting.

Medications commonly used via subcutaneous infusion (e.g., syringe driver):

· Morphine sulfate 2.5–5 mg subcutaneously every 4 hours as needed for pain/dyspnoea, or as continuous infusion if frequent doses are required.

· Midazolam 2.5–5 mg subcutaneously as needed for agitation or terminal restlessness.

· Glycopyrronium 0.2–0.4 mg subcutaneously every 6 hours as needed for respiratory secretions.

· Haloperidol or levomepromazine for nausea, vomiting, or severe agitation.

Doses must be individualised, and regular review is essential. Non-essential medications, including iron chelators, prophylactic antibiotics, and routine laboratory monitoring, should usually be stopped to reduce treatment burden [6,8].

6.4 Communication and Bereavement

· Communicate clearly and compassionately with the patient and family.

· Use an interpreter when needed.

· Provide written information about what to expect.

· Offer spiritual and cultural support.

· Arrange bereavement follow-up for the family.

7. Integrating Palliative Care into Haemolytic Disease Services

Palliative care should not be a separate service used only at the end of life. Integration can occur through:

· Primary palliative care: Haematology teams trained in basic symptom management and advance care planning.

· Specialist palliative care: Referral for complex pain, refractory symptoms, psychosocial distress, or end-of-life care.

· Shared care models: Joint clinics with haematology and palliative care, particularly for sickle cell disease and thalassaemia.

Early palliative care in advanced cancer has been shown to improve quality of life and mood, and similar benefits are increasingly recognised in life-limiting haematological disorders [14]. In sickle cell disease, guidelines encourage comprehensive pain management and early involvement of palliative care services for patients with severe or recurrent complications [2,3].

8. Conclusion

Haemolytic disease, whether inherited or acquired, imposes a substantial burden of anaemia, pain, organ dysfunction, and psychological distress. Palliative care is an essential component of comprehensive management and should be introduced early, alongside disease-directed therapies. Effective symptom control—especially pain, dyspnoea, fatigue, and pruritus—requires a multidisciplinary approach and close collaboration between haematology and palliative care teams. In severe haemolytic disease of the fetus and newborn, perinatal palliative care provides families with compassionate support and allows for comfort-focused care when cure is not possible. Advance care planning and end-of-life care must be individualised, culturally sensitive, and centred on the patient’s goals and values.

References

1. World Health Organization. Palliative Care. 5 August 2020. https://www.who.int/news-room/fact-sheets/detail/palliative-care

2. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Bethesda, MD: National Institutes of Health; 2014.

3. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517

4. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and strategies for red blood cell transfusion. Cochrane Database Syst Rev. 2016;10(10):CD002042. doi:10.1002/14651858.CD002042.pub4

5. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435-452. doi:10.1164/rccm.201111-2042ST

6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Palliative Care. Version 1.2023. https://www.nccn.org

7. National Institute for Health and Care Excellence. Sickle cell disease: managing acute painful episodes in hospital. Clinical guideline [CG143]. 2012. https://www.nice.org.uk/guidance/cg143

8. National Institute for Health and Care Excellence. Care of dying adults in the last 

days of life. NICE guideline [NG31]. 2015. https://www.nice.org.uk/guidance/ng31

9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267. doi:10.1016/j.jhep.2009.04.009

10. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895. doi:10.1056/NEJMoa035477

11. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. Am J Hematol. 2010;85(10):831-833. doi:10.1002/ajh.21838

12. Qureshi H, Massey E, Kirwan D, et al. BSH guideline for the management of haemolytic disease of the fetus and newborn. Br J Haematol. 2016;173(5):680-693. doi:10.1111/bjh.14119

13. ACOG Committee Opinion No. 786: Perinatal Palliative Care. Obstet Gynecol. 2019;134(3):e84-e89. doi:10.1097/AOG.0000000000003425

14. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678